Why the study?
The active components and mechanisms of action of KuShen and XiYangShen combination therapy for treating myocarditis remain unclear.
Does the combination of KuShen and XiYangShen (KX) improve myocardial injury and reduce inflammatory factors in an experimental autoimmune myocarditis model?
Population
Experimental autoimmune myocarditis animal model
Comparison
KX treatment vs untreated experimental autoimmune myocarditis
Design
Network pharmacology and animal experimental study
Key result
The combination of KuShen and XiYangShen (KX) ameliorated myocardial injury and dose-dependently inhibited the secretion of inflammatory factors in an animal model of myocarditis.
Authors
Loading...
Hypothesis-generating for KX in myocarditis models; leaves open clinical translation pending human trials.
Does the combination of KuShen and XiYangShen (KX) improve myocardial injury and reduce inflammatory factors in an experimental autoimmune myocarditis model?
The combination of KuShen and XiYangShen ameliorates myocardial injury in experimental autoimmune myocarditis by inhibiting inflammatory factor secretion and modulating the Th17 cell differentiation pathway.
Liu et al. (2022) studied Myocarditis. Combination of KuShen and XiYangShen (KX) vs. Experimental autoimmune myocarditis (EAM) group was evaluated on Myocardial injury and inflammatory factor secretion. The combination of KuShen and XiYangShen (KX) ameliorated myocardial injury and dose-dependently inhibited the secretion of inflammatory factors in an animal model of myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: